Vanesa Gutiérrez

622 total citations
13 papers, 134 citations indexed

About

Vanesa Gutiérrez is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Vanesa Gutiérrez has authored 13 papers receiving a total of 134 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 2 papers in Surgery. Recurrent topics in Vanesa Gutiérrez's work include Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Lung Cancer Research Studies (4 papers). Vanesa Gutiérrez is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Lung Cancer Research Studies (4 papers). Vanesa Gutiérrez collaborates with scholars based in Spain, France and Greece. Vanesa Gutiérrez's co-authors include Ramaswamy Govindan, Martin Reck, Ivor Percent, Christine Baudelet, Daniel Morgensztern, Jerónimo Rafael Rodríguez‐Cid, Neal Ready, Solange Peters, Alejandro Navarro and K. Park and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and BMC Cancer.

In The Last Decade

Vanesa Gutiérrez

11 papers receiving 130 citations

Peers

Vanesa Gutiérrez

ONCOL

PRM

EPIDE

José Antonio López-Vilariño Spain

J. Letreut France

Marc Cucurull Spain

Christian Boch Germany

Alice Baggi Italy

Jacob Vinson United States

Alexey Smolin Russia

Jocelyn Booth United States

Natalie Byrne United Kingdom

Yuanbin Chen United States

José Antonio López-Vilariño Spain

Vanesa Gutiérrez

133 ×1.2

ONCOL

44 ×0.7

PRM

83 ×1.6

EPIDE

83 ×1.8

14 ×0.7

Citations per year, relative to Vanesa Gutiérrez Vanesa Gutiérrez (= 1×) peers José Antonio López-Vilariño

Countries citing papers authored by Vanesa Gutiérrez

Since Specialization

Citations

This map shows the geographic impact of Vanesa Gutiérrez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanesa Gutiérrez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanesa Gutiérrez more than expected).

Fields of papers citing papers by Vanesa Gutiérrez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanesa Gutiérrez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanesa Gutiérrez. The network helps show where Vanesa Gutiérrez may publish in the future.

Co-authorship network of co-authors of Vanesa Gutiérrez

This figure shows the co-authorship network connecting the top 25 collaborators of Vanesa Gutiérrez. A scholar is included among the top collaborators of Vanesa Gutiérrez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanesa Gutiérrez. Vanesa Gutiérrez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Jurado, J.M., Vanesa Gutiérrez, Miguel‐Ángel Berciano‐Guerrero, et al.. (2025). Association Between Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 14(7). 2499–2499.

Gregorc, Vanesa, María González‐Cao, Stefania Salvagni, et al.. (2024). KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.. Journal of Clinical Oncology. 42(17_suppl). LBA8511–LBA8511. 14 indexed citations

Felip, Enriqueta, Byoung Chul Cho, Vanesa Gutiérrez, et al.. (2024). Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.. Journal of Clinical Oncology. 42(16_suppl). 8504–8504. 8 indexed citations

Navarro, Alejandro, Egbert F. Smit, Enric Carcereny, et al.. (2023). P2.17-06 Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial. Journal of Thoracic Oncology. 18(11). S380–S381.

Pérez-Ruiz, Elísabeth, et al.. (2021). Liquid Biopsy as a Tool for the Characterisation and Early Detection of the Field Cancerization Effect in Patients with Oral Cavity Carcinoma. Biomedicines. 9(10). 1478–1478. 5 indexed citations

Owonikoko, Taofeek K., Ramaswamy Govindan, Neal Ready, et al.. (2019). Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. Annals of Oncology. 30. ii77–ii77. 66 indexed citations

Arriola, Edurne, Ramón García Gómez, Pilar Díz, et al.. (2018). Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 18(1). 106–106. 14 indexed citations

Parra‐Medina, Rafael, et al.. (2018). Colonic adenosquamous carcinoma and mucinous adenocarcinoma with microsatellite instability.. PubMed. 40(2). 199–202. 4 indexed citations

Cobo, Manuel, Vanesa Gutiérrez, José Trigo, et al.. (2017). Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity. PubMed. Volume 8. 57–66. 8 indexed citations

10.

Cobo, Manuel, et al.. (2016). Afatinib en pacientes con carcinoma escamoso de pulmón: contexto actual y opción de un tratamiento oral. Medicina Clínica. 146. 25–29. 3 indexed citations

11.

Cobo, Manuel, et al.. (2009). Phase II trial of erlotinib maintenance therapy after platinun-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). e19013–e19013. 1 indexed citations

12.

Cobo, Manuel, Vanesa Gutiérrez, Julia Alcaide, et al.. (2007). A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status. Lung Cancer. 56(2). 255–262. 8 indexed citations

13.

Urra, José Miguel, et al.. (1992). Tumor necrosis factor alpha is released by monocytes in OKT3 monoclonal antibody immunosuppressive therapy.. PubMed. 24(6). 2542–4. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact